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Abstract
Aim: To determine the effectiveness of a formula diet in weight reduction and the re-
covery of menstruation in obese patients with ovulatory disorders.
Methods: After the enrollment of 39 obese women with ovulatory disorders, they 
replaced one or two of their three normal meals with a microdiet (MD) (240 kcal/meal) 
for 24 weeks. Physical, endocrinological, and biochemical tests were conducted be-
fore and at 12 and 24 weeks of the study. Of the 39 women enrolled, 26 were not 
taking clomiphene. They were divided into three groups according to their body 
weight outcomes and then analyzed for menstruation recovery.
Results: A weight reduction of ≥5% was observed in 31 (81.5%) of the 39 women. 
There were significant decreases in the body weight and Body Mass Index during the 
study. Menstruation returned in 18 (69%) of the 26 patients without clomiphene 
treatment, with the recovery being significantly more prevalent in the groups (totally 
81.0%) that exhibited a 5%- 10% weight reduction and ≥10% weight reduction, com-
pared to the group with a <5% weight reduction.
Conclusion: The use of a formula diet effectively reduced the patients’ body weight 
and led to the recovery of menstruation in these obese patients with ovulatory 
disorders.
K E Y W O R D S
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1  | INTRODUCTION
Obesity is rapidly increasing and becoming a major cause of disease 
and death throughout the world.1,2 In 2014, there were 1.9 bil-
lion overweight and 600 million obese adults in the world, with this 
obesity more common in women, compared to men. Obesity also has 
been known to be a risk factor for anovulation, ovulatory disorder, 
lower pregnancy rates in subfertility, and polycystic ovary syndrome 
(PCOS).3,4 Ovulatory disorders in patients with PCOS have been re-
ported to improve in conjunction with the loss of weight.5,6 In cases 
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where patients are not able to successfully lose weight, the induction of 
ovulation is usually attempted during infertility treatments. However, 
in order to achieve ovulation in obese patients, high doses of the ovu-
lation induction drugs are usually required.7 It has been reported that 
a high body mass index (BMI) increases the consumed gonadotropin 
ampoules and there is a longer treatment duration, together with a 
decreased number of collected oocytes,8,9 which is costly10 in in vitro 
fertilization. Furthermore, side- effects such as miscarriage and a low 
pregnancy rate, cycle cancelation, and/or the ineffectiveness of the 
treatment option are more prevalent in obese patients.9 Thus, scien-
tific evidence has shown that weight loss treatment options are just 
as effective as any of the high- cost treatments that are normally used 
when trying to treat patients with infertility and ovulatory disorder. 
Currently, however, there are only a few good ways that can effectively 
and successfully reduce body weight. Formula diets are often used for 
weight loss treatments, as they contain fewer carbohydrate and lipid 
products while still providing sufficient protein, vitamins, and all of the 
necessary minerals.11,12 The microdiet® (MD, Sunny Health Company, 
Ltd., Tokyo, Japan) is a formula diet that is used to maintain the nor-
mal functions of the living body and suppress the body protein to a 
minimum level so that the body can lose excess fat by more efficiently 
burning calories. In 1983, a research group led by Jacqueline Stordy at 
the University of Surrey in the UK first created MD for use as a hospital 
diet, which was based on the very- low- calorie diet (LCD) theory, and 
is an ultra- low- calorie, high- nutrition food. The consumption of MD 
instead of a normal meal helps to create a greater energy deficit be-
tween the energy requirement and the dietary energy intake. Two daily 
servings of MD supplies all of the nutrients required for 1 day, while 
only containing 480 kcal. When administered to obese patients with 
type 2 diabetes who were taking part in a weight reduction program, 
a high success rate was reported for MD.11 The current study further 
examined the effectiveness of MD in weight reduction (WR) and in the 
recovery of menstruation in obese patients with ovulatory disorders.
2  | MATERIALS AND METHODS
2.1 | Study design
This study was conducted in the departments of Obstetrics and 
Gynecology at Tokushima University, Kagoshima University, Saitama 
Medical University, St. Marianna University of Medicine, University of 
Fukui, and Kawano Mika Lady’s Clinic. All the procedures were con-
ducted after obtaining approval from the institutional review boards 
(Approved No. 377). All the patients provided written informed con-
sent prior to the start of the study.
2.2 | Participants
This study enrolled 45 women with ovulatory disorders (including 21 
women with PCOS, as diagnosed by the Japanese PCOS criteria,13,14 
all of which also meet the Rotterdam criteria,15 and a BMI of ≥25. All 
of them did not have menstruation for at least 2 months. Table 1 pre-
sents the baseline characteristics of the patients. Those patients with 
severe underlying diseases that prohibited a LCD (600- 1200 kcal/d), 
a known allergy to any of the products, including MD, limited compe-
tence for consent under the Civil Code, hyperprolactinemia, ovula-
tion failure associated with high serum follicle stimulating hormone 
(FSH), and who were pregnant or potentially pregnant women, nurs-
ing women, or who were considered to be inappropriate for LCD 
therapy by the physician were excluded from the study. During the 
experimental period, one patient withdrew from the study after being 
confirmed to be pregnant. In addition, all the patients were prohibited 
from undergoing sex hormone treatments during the study.
2.3 | Interventions and outcomes
Microdiet® (240 kcal/meal, provided by Sunny Health Company, 
Ltd., Tokyo, Japan) was provided as a replacement for one or two of 
the three normal meals that were consumed each day for a period 
of 24 weeks (Figure 1). Throughout the study, all the participants 
underwent physical examinations, blood pressure measurements, 
transvaginal ultrasonography (Tv- USG), the testing of the serum con-
centrations of estradiol (E2) and progesterone (P4) at 4 week intervals 
and the serum concentrations of luteinizing hormone (LH), FSH, and 
testosterone (T) at 8 week intervals. Each patient’s weight, height, and 
hip and waist circumferences were measured and used to calculate 
the BMI. At 12 and 24 weeks after the beginning of the study, blood 
samples were collected after a 12 hours overnight fast and were ana-
lyzed by using commercial kits and automated analyzers in order to 
determine the hormonal changes, kidney function, liver function, and 
the enzyme and lipid profiles. All the patients recorded their basal 
body temperature (BBT) throughout the study. The recovery of men-
struation was assessed every 4 weeks by the biphasic BBT pattern, 
which was verified by hormonal data and morphological Tv- USG find-
ings of the endometrium and ovaries. During the study, 13 patients 
were excluded from the analysis of menstruation due to taking clomi-
phene. The remaining 26 patients who did not take clomiphene were 
divided into three groups according to their body WR (<5% WR [n=5]; 
5%- 10% WR [n=5], and ≥10% WR [n=16]) and then were analyzed for 
menstruation recovery. The recovery of menstruation was defined as 
an experience of menstruation at least once during the study. Those 
patients who had or did not have a recovery of menstruation were 
grouped as “eumenorrheic” or “amenorrheic,” respectively.
2.4 | Assays
The serum FSH and LH concentrations were measured by using a 
chemiluminescent immunoassay kit (Abbott Company, Tokyo, Japan). 
The E2 concentration was measured by an electrochemiluminescence 
immunoassay kit (ECLusys Estradiol II; Roche Diagnostics, K.K., Tokyo, 
Japan). The serum T concentration was measured by an electrochemi-
luminescence immunoassay kit (ECLusys TESTO II; Roche Diagnostics, 
K.K.). The serum prolactin and P4 were measured by using an 
enzyme- linked immunosorbent assay kit (Abcam, Tokyo, Japan). The 
serum aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), lactate dehydrogenase, gamma- glutamyltransferase, alkaline 
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phosphatase, total bilirubin, and total protein levels were measured by 
using an automated clinical analyzer (Hitachi, Tokyo, Japan). The fast-
ing blood sugar (FBS) was measured by a glucose analyzer (GA04; A&T 
Corporation, Kanagawa, Japan), while the fasting immunoreactive in-
sulin (IRI) was measured by using an enzyme immunoassay (AIA2000; 
TOSOH Company, Tokyo, Japan). Insulin resistance was calculated by 
Characteristic Unit N Mean ± SD Minimum Maximum
Age years 45 29.5±5.5 20.0 38.0
Height cm 45 158.0±5.0 147.0 170.0
Weight kg 45 85.1±15.8 60.5 134.8
Body mass index kg/m2 45 34.2±5.7 24.9 50.1
Waist (W) cm 34 101.5±13.7 82.0 128.4
Hip (H) cm 34 109.4±9.4 93.1 130.0
W–H ratio 34 0.93±0.07 0.82 1.13
Systolic BP mm Hg 26 131±18 102 162
Diastolic BP mm Hg 25 84±13 62 116
Serum prolactin ng/mL 34 6.7±4.5 1.7 21.6
FSH mIU/mL 45 7.0±3.2 1.2 21.5
LH mIU/mL 44 8.1±5.3 0.3 24.0
LH–FSH ratio 44 1.2±0.60 0.1 2.8
Estradiol pg/mL 41 45.0±28.0 10.0 156.0
Progesterone ng/mL 41 1.2±2.3 0.2 11.9
Testosterone ng/mL 43 0.7±0.6 0.1 2.8
AST IU/L 43 29±18 12 114
ALT IU/L 43 40±26 11 136
LDH IU/L 43 197±38 138 291
γ- GTP IU/L 43 46±59 7 324
ALP IU/L 43 231±62 137 472
Total bilirubin mg/dL 42 0.6±0.3 0.0 1.2
Total protein mg/dL 41 7.6±0.5 6.7 8.7
FBS mg/dL 42 111±38 79 232
IRI μIU/mL 41 37.4±56.2 4.2 297
Total cholesterol mg/dL 43 207±33 106 275
Triglyceride mg/dL 43 182±159 34 1008
HDL- C mg/dL 40 57±34 34 260
BUN mg/dL 41 11.8±3.2 4.0 20.0
Uric acid mg/dL 40 5.7±1.2 3.5 8.0
Creatinine mg/dL 40 0.60±0.10 0.39 1.00
WBC /μL 41 7964±1913 4180 11 300
RBC ×104/μL 41 469±85 419 576
Hemoglobin g/dL 41 14.2±1.1 11.3 16.0
Ht % 41 42.7±3.1 34.0 47.5
MCV μm3 41 89.10±5.1 81.1 102.0
MCH pg 41 29.70±1.9 26.5 35.0
MCHC % 41 33.3±0.7 32.0 35.0
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood 
pressure; BUN, blood urea nitrogen; FBS, fasting blood sugar; FSH, follicle stimulating hormone; GTP, 
glutamyltransferase; HDL- C, high- density lipoprotein cholesterol; HOMA- IR, homeostasis model as-
sessment of insulin resistance; Ht, hematocrit; IRI, fasting immunoreactive insulin; LDH, lactate dehy-
drogenase; LH, luteinizing hormone; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular 
hemoglobin concentration; MCV, mean corpuscular volume; RBC, red blood cell; SD, standard devia-
tion; WBC, white blood cell.
TABLE  1 Baseline characteristics of the 
patients
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the following formula: homeostasis model assessment of insulin re-
sistance (HOMA- IR)=IRI (μIU/mL)×FBS (mg/dL)/405. The serum lipid 
profiles were determined by using total cholesterol (T- Cho), triglycer-
ides (TG), and high- density lipoprotein cholesterol, while the kidney 
function was determined by using creatinine, blood urea nitrogen, and 
uric acid. They all were analyzed through the use of automated clinical 
analyzers (Hitachi, Tokyo, Japan). Additionally, the hematological pro-
files (white blood cells, red blood cells, hemoglobin, hematocrit (Ht), 
mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), mean corpuscular volume (MCV)) were ana-
lyzed by an automated analyzer.
2.5 | Statistical analysis
All the data are presented as mean±SD values. All the statistical anal-
yses were performed by using a one- way or two- way ANOVA and 
post- hoc tests. The categorical data analysis was performed by using 
the chi square test. P<.05 was considered to be statistically significant.
3  | RESULTS
Out of the 45 patients who were enrolled in the study, 39 (which in-
cluded the one patient who became pregnant during the study) com-
pleted the study protocol (Figure 2). There were 21 patients who were 
diagnosed with PCOS. Thirteen of the patients were excluded from 
the menstruation analysis, as they were found to be using clomiphene 
for the induction of ovulation. Table 1 presents the baseline charac-
teristics of the patients. They were overweight or obese (BMI≥25).
Of the 39 patients who completed the study, 38 lost weight, while 
one patient gained weight. After excluding the one patient who be-
came pregnant, the results showed that a WR of >5% was achieved 
by 31 (81.5%) out of the 38 patients (Figure 3). Also, the WRs of 10% 
were achieved by 21 (55.2%) patients.
After 24 weeks, there was a significant decrease in the mean 
body weight of all the patients, with weights decreasing from 84 kg to 
75 kg (11%) (P<.01) (Figure 4). The BMI decreased from 34.0 kg/m2 to 
30.3 kg/m2 (10.9%) (P<.01). The waist circumference decreased from 
101 cm to 92 cm (8.9%) (P<.05). The hip circumference decreased 
from 109 cm to 102 cm (6.4%) (P<.05). When compared to the values 
that had been obtained prior to the study, there were significant de-
creases in the HOMA- IR, FBS, T- Cho, TG, AST, and ALT after 12 and 
24 weeks (Figure 5).
Out of the 26 patients that did not take clomiphene, menstruation 
recovered in 18 (69%) of the patients without the induction of ovula-
tion (Table 2, Figure 6). Table 2 shows the presence of menstruation be-
fore and during the study of each patient with WR data. Menstruation 
recovered in accordance with the body WR percentages, with the re-
covery of menstruation observed in one of five patients (20%) who was 
in the <5% WR group, in five out of five patients (100%) who had a 5%- 
10% WR, and in 12 of the 16 patients (75%) with >10% WR (Figure 6), 
showing as high as 81.0% (17 patients) recovery of menstruation 
F IGURE  2 Analyzed patients. A total of 45 patients was enrolled 
in the study, with 39 completing the study and 26 who were not 
taking clomiphene being analyzed for the recovery of menstruation. 
PCOS, polycystic ovary syndrome
F IGURE  3 Proportion of weight reduction during the study. There 
was a significant reduction in the body weight of 31 (81.5%) out of 
38 patients. At 24 weeks, one patient was excluded from the weight 
reduction analysis due to pregnancy. WR, weight reduction
F IGURE  1 Study protocol. The participants with a body mass 
index (BMI) of ≥25 were enrolled in this study for 24 weeks. MD, 
microdiet®, which contained 240 kcal/meal
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among total 21 patients with >5% WR. A significantly higher recovery 
of menstruation (more than twice during the study) was seen in both 
the 5%- 10% WR group (P<.05) and the >10% WR group (P<.01), as 
compared to the <5% WR group.
The eumenorrheic patients, who recovered menstruation at least 
once, exhibited a significantly lower T level at 24 weeks, compared to 
the amenorrheic patients, who did not recover menstruation during 
the study (P<.01). The T- levels increased from baseline to 12 weeks 
and then significantly decreased between 12 and 24 weeks in the 
amenorrheic patients (P<.05) (Figure 7). Although the eumenorrheic 
patients tended to have higher baseline IRI levels, there was no sig-
nificant difference observed for the IRI between the amenorrheic 
and eumenorrheic patients in this study. The PCOS–amenorrheic 
patients exhibited significantly higher T- levels, compared to the 
non- PCOS–eumenorrheic patients, at 12 and 24 weeks (P<.01). The 
PCOS–amenorrheic patients also had significantly higher T- levels, 
compared to the PCOS–eumenorrheic patients, at 12 (P<.05) and 
24 weeks (P<.01).
4  | DISCUSSION
It is well known that obese patients have ovulatory disorders, a low 
rate of natural cycles, a high rate of miscarriage, and congenital anoma-
lies.3,10,16 In women with ovulatory disorders, WR has been shown to 
improve both menstruation and reproductive parameters. A previous 
study reported that spontaneous ovulation recovered in obese women 
at 6 months after WR.10 These women also had an increased rate of 
achieving pregnancy and live births and a reduced miscarriage rate, all 
of which led to a decreased financial cost, as compared to that incurred 
when undergoing infertility treatments.10 More recently, a formula 
diet also was successfully used to achieve WR in obese patients.11,12 
F IGURE  4 Body measurement 
changes. A, Weight; B, body mass index; 
C, waist circumference; and D, hip 
circumference. The data are expressed 
as the mean±SD. *P<.05 and **P<.01
F IGURE  5 Blood biochemistry 
changes. The (A) homeostasis model 
assessment of insulin resistance, (B) 
total cholesterol, (C) triglyceride, (D) 
fasting blood sugar, (E) aspartate 
aminotransferase, and (F) alanine 
aminotransferase all were significantly 
decreased. The data are expressed as 
the mean ± standard deviation. *P<.05 
and **P<.01
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Therefore, it was decided to investigate further the MD formula diet 
and to evaluate the ability of this diet to reduce body weight and to 
recover menstruation in obese patients with ovulatory disorders. 
Menstruation recovered in 81% (17/21) of the patients who achieved 
a >5% weight loss. These results demonstrated that the use of the MD 
formula diet led to a significant weight loss and the achievement of reg-
ular menstruation in overweight women, including those with PCOS.
Also, WR and weight maintenance are very important in helping to 
reduce the morbidity and mortality that are associated with cardiovas-
cular diseases, diabetes, osteoarthritis, and obstructive sleep apnea.17–
19 One study reported a 16% reduction in the incidence of diabetes for 
each 1 kg of weight loss.20 In the current study, 24 out of the 26 pa-
tients showed a WR of at least 1 kg in 4 weeks, which indicated that the 
diabetic risk was markedly reduced. The National Institute for Clinical 
Excellence guidelines reported that a 5%- 10% weight loss or a 0.5- 1 kg 
weekly reduction is the best range for successful weight loss, as this 
is associated with large improvements in symptoms and metabolic 
parameters.21 In this study, 35.8% of the patients achieved a >5% WR 
in only 4 weeks by using MD; furthermore, as high as 69.2% and 81.5% 
of the patients did that after 12 and 24 weeks, respectively. The met-
abolic parameters (HOMA- IR, FBS, T- Cho, TG) and liver function tests 
(AST, ALT) also were markedly improved after 12 or 24 weeks. A study 
reported that the FBS, HOMA- IR, and insulin were apparently lower 
in the formula diet group using MD than in the group using a conven-
tional Japanese low- caloric diet.11 In their report, the metabolic param-
eters also improved just as in this study. From these results, MD, which 
contains a rich level of protein and a poor level of carbohydrate, is help-
ful in order to reduce one’s body weight and to improve the metabolic 
parameters. Although there are many choices for WR treatments, such 
as exercise, anti- obesity drugs, lifestyle modification, bariatric surgery, 
and diet, these treatments are not always effective, nor do they always 
successfully reduce the body weight. Meal replacements or substitu-
tion with a LCD can be used to maintain weight loss with no adverse 
effect, in addition to having a similar efficacy as anti- obesity drugs and 
No. PCOS
Weight reduction (%) and recovery of menstruation before and during the 
study (weeks)
−4- 0 0- 4 4- 8 8- 12 12- 16 16- 20 20- 24
1 Yes 0.0 −3.9 −5.4 −7.0 −8.2 −7.3 −10.4
2 Yes 0.0 −5.6 −8.1 −8.9 −11.7 −11.1 −12.5
3 Yes 0.0 −1.9 −5.6 −7.2 −7.6 −9.4 −12.0
4 Yes 0.0 −3.1 −3.1 −3.8 −5.0 −5.4 −5.1
5 Yes 0.0 −2.8 −4.2 −2.8 −5.0 −6.1 −7.2
6 Yes 0.0 −3.3 −8.6 −8.7 −10.1 −11.0 −11.3
7 Yes 0.0 −5.8 −9.7 −12.4 −13.6 −16.6 −19.3
8 Yes 0.0 −3.9 −9.5 −14.0 −14.0 −16.4 −17.3
9 Yes 0.0 −2.6 −3.5 −5.6 −3.8 −3.8 −3.5
10 Yes 0.0 −2.9 −4.2 −4.1 −4.3 −4.7 −3.4
11 Yes 0.0 −3.9 −9.5 −10.8 −15.7 −15.8 −16.6
12 No 0.0 −1.8 −4.5 −4.5 −4.9 −5.0 −6.8
13 No 0.0 −5.6 −10.3 −11.0 −13.2 −12.4 −14.5
14 No 0.0 −8.1 −13.0 −15.5 −15.2 −16.9 −19.4
15 No 0.0 −5.8 −8.6 −11.3 −13.3 −16.0
16 No 0.0 −2.3 −2.7 −3.6 −4.6 −5.0 −7.5
17 No 0.0 −2.3 −7.7 −10.5 −12.4 −12.3 −13.3
18 No 0.0 −1.1 −1.3 −0.4 −1.1 −2.4 −3.2
19 No 0.0 −5.4 −8.2 −10.0 −11.4 −11.7 −11.7
20 No 0.0 −5.5 −6.4 −8.2 −8.5 −10.6 −10.2
21 No 0.0 −5.0 −5.4 −5.8 −5.9 −5.4 −5.9
22 No 0.0 −6.2 −9.8 −12.0 −13.2 −13.6 −15.0
23 No 0.0 0.1 −1.0 −0.8 −1.0 −2.6 −2.0
24 No 0.0 −6.1 −10.8 −14.4 −20.3 −23.2 −26.9
25 No 0.0 −4.6 −7.8 −10.0 −14.3 −13.6 −15.7
26 No 0.0 0.6 1.8 1.8 1.4 1.6 4.1
The shading represents the presence of menstruation. PCOS, polycystic ovary syndrome. Case No.15 
conceived during the study due to recovery of ovulation. Therefore, her data of 20-24 weeks was miss-
ing and excluded from analysis.
TABLE  2 Presence of menstruation in 
the patients without ovulation induction
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at a lower cost.12,22 Studies in many fields have examined reductions in 
body weight and the maintenance of weight. One reported finding that 
a protein- sparing, modified fasting (~1.2- 1.4 g protein/kg) diet was ef-
fective in reducing the body weight as long as the patients also were 
placed on a full vitamin and mineral supplementation regimen.23 In re-
cent years, this therapy has become much easier to perform through 
the use of a formula diet, such as MD, which contains high protein, 
low carbohydrate, and low fat, while being rich in vitamins and miner-
als, all of which are required for wellness.11 The MD not only reduces 
body weight and improves the coronary risk factors in obese patients 
with type 2 diabetes, but it also helps to reduce operative risks and 
to improve postoperative results.24 Additionally, there was no adverse 
effect during MD treatment in this study, suggesting that MD is a safe 
method to use to reduce body weight.
In PCOS, ~30%- 75% of these patients are found to be obese.25 
When obesity is present, this induces insulin resistance and hy-
perinsulinemia. As a result, this inhibits the production of the sex 
hormone- binding globulin (SHBG) in the liver, thereby causing hyper-
androgenism. Subsequently, the increased androgen is converted to 
estrogen in the adipose tissue and ovary, thereby suppressing gonad-
otropin secretion.3,26 In this study, the IRI decreased but the T- level 
did not decrease in the patients who recovered menstruation. The re-
covery of menstruation might be brought about mainly by a reduced 
free T- concentration through an increased SHBG concentration. In 
contrast, the amenorrheic patients showed an elevation of the serum 
T during WR, especially if they had PCOS. Some mechanisms would 
exist in relation to PCOS pathophysiology; however, further study 
would be needed to clarify these mechanisms. Moreover, as obesity 
also reduces serum adiponectin, this can lead to incremental increases 
in the amount of insulin circulating within the body.27 Thus, in order 
to achieve the recovery of ovulation in patients with PCOS, they need 
to consider undergoing potential weight loss treatment. Previous stud-
ies have reported that after a WR of at least 5%- 10% in patients with 
PCOS, there were increases in the insulin sensitivity and SHBG levels, 
normalized reproductive hormone profiles, restored menstrual cyclicity, 
an improvement in infertility symptoms, and a reduction in cardiovas-
cular risks and comorbidities.28,29 One study reported that the use of 
short- term LCDs improved the reproductive and metabolic parameters, 
with >50% of the women exhibiting menstruation recovery.30 In this 
study, the serum insulin level decreased in accordance with PCOS. The 
patients who recovered menstruation tended to have a higher insulin 
level at the beginning of the study than those who did not recover men-
struation. Higher serum insulin might be a predictor of menstruation 
recovery in response to WR and might indicate further involvement 
F IGURE  6 Recovery of menstruation in accordance with the 
level of weight reduction (WR). A, Of the 26 patients not taking 
clomiphene, 18 recovered menstruation without the induction of 
ovulation. B, As for the recovery of menstruation more than twice 
during the study, the percentage was significantly higher in the 5%- 
10% and in the >10% WR groups. The recovery rate of menstruation 
was totally 81.0% (17/21) in patients with >5% WR. *P<.05 and 
**P<.01. Amenorrheic, no recovery of menstruation during the study; 
eumenorrheic, recovery of menstruation at least once during the 
study; WR, weight reduction
F IGURE  7  (A and B) Serum 
testosterone and (C and D) fasting 
immunoreactive insulin level 
changes. In the 26 patients who 
were not taking clomiphene, eight 
were amenorrheic and 18 were 
eumenorrheic. Considering the 
background of polycystic ovary 
syndrome (PCOS), eight were 
PCOS–eumenorrheic, three were 
PCOS–amenorrheic, 10 were non- 
PCOS–eumenorrheic, and five were 
non- PCOS–amenorrheic. The data 
are expressed as the mean±SD. 
*P<.05 and **P<.01. Amenorrheic, 
no recovery of menstruation during 
the study; eumenorrheic, recovery of 
menstruation at least once during the 
study
     |  275MATSUZAKI eT Al.
of hyperinsulinemia for anovulation in this group. Although both the 
use of a formula diet or a calorie- restricted weight loss regimen can 
lead to short- term significant reductions in weight, it is important that 
long- term weight maintenance also be taken into consideration. The 
results of this study showed that 81.5% of all of the patients exhibited 
a weight loss of ≥5% and 81.0% (17/21 patients) experienced menstru-
ation recovery. As long- term WR also is required to improve reproduc-
tive function, the long- term use of MD might be effective for use in 
patients with reproductive issues. In conclusion, the use of the MD as 
a WR regimen effectively reduced the body weight of obese patients 
with ovulatory disorders and assisted them in menstruation recovery.
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